Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBT (2016 - 2025)

Historic EBT for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $60.0 million.

  • Haemonetics' EBT rose 2014.94% to $60.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $227.2 million, marking a year-over-year increase of 3788.7%. This contributed to the annual value of $212.1 million for FY2025, which is 3964.44% up from last year.
  • According to the latest figures from Q4 2025, Haemonetics' EBT is $60.0 million, which was up 2014.94% from $51.3 million recorded in Q3 2025.
  • Haemonetics' EBT's 5-year high stood at $70.7 million during Q1 2025, with a 5-year trough of -$27.4 million in Q2 2021.
  • In the last 5 years, Haemonetics' EBT had a median value of $41.6 million in 2022 and averaged $34.9 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 22475.87% in 2021, then skyrocketed by 94753.99% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' EBT stood at $19.9 million in 2021, then soared by 111.95% to $42.2 million in 2022, then increased by 4.27% to $44.0 million in 2023, then grew by 13.37% to $49.9 million in 2024, then increased by 20.15% to $60.0 million in 2025.
  • Its EBT was $60.0 million in Q4 2025, compared to $51.3 million in Q3 2025 and $45.2 million in Q2 2025.